Charles Owens

Mr. Charles Owens

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
JSJoseph L Sottnik
Joseph L Sottnik
LVLauren Vanderlinden
Lauren Vanderlinden
MJMolishree Joshi
Molishree Joshi
ACAna Chauca-Diaz
Ana Chauca-Diaz
COCharles Owens
Charles Owens
DTDan Theodorescu
Dan Theodorescu
The androgen receptor (AR) is important in the development of both experimental and human bladder cancer. However, the role of AR in bladder cancer growth and progression is less clear, with literature indicating that more advanced stage and grade disease are associated with reduced AR expression. To determine the mechanisms underlying these relationships, we profiled AR-expressing human bladder cancer cells by AR chromatin immunoprecipitation sequencing and complementary transcriptomic approaches in response to in vitro stimulation by the synthetic androgen R1881. In vivo functional genomics consisting of pooled shRNA or pooled open reading frame libraries was employed to evaluate 97 genes that recapitulate the direction of expression associated with androgen stimulation. Interestingly, we identified CD44, the receptor for hyaluronic acid, a potent biomarker and driver of progressive disease in multiple tumor types, as significantly associated with androgen stimulation. CRISPR-based mutagenesis of androgen response elements associated with CD44 identified a novel silencer element leading to the direct transcriptional repression of CD44 expression. In human patients with bladder cancer, tumor AR and CD44 mRNA and protein expression were inversely correlated, suggesting a clinically relevant AR–CD44 axis. Collectively, our work describes a novel mechanism partly explaining the inverse relationship between AR and bladder cancer tumor progression and suggests that AR and CD44 expression may be useful for prognostication and therapeutic selection in primary bladder cancer. Significance: This study describes novel AREs that suppress CD44 and an expected inverse correlation of AR-CD44 expression observed in human bladder tumors.

19 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SLSeungjae Lee
Seungjae Lee
TCTi-Cheng Chang
Ti-Cheng Chang
PSPatrick Schreiner
Patrick Schreiner
YFYiping Fan
Yiping Fan
NANeeraj Agarwal
Neeraj Agarwal
Armita BahramiArmita Bahrami
Armita Bahrami
Background: TERT promoter methylation, located several hundred base pairs upstream of the transcriptional start site, is cancer specific and correlates with increased TERT mRNA expression and poorer patient outcome. Promoter methylation, however, is not mutually exclusive to TERT activating genetic alterations, as predicted for functionally redundant mechanisms. To annotate the altered patterns of TERT promoter methylation and their relationship with gene expression, we applied a Pacific Biosciences-based, long-read, bisulfite-sequencing technology and compared the differences in the methylation marks between wild-type and mutant cancers in an allele-specific manner. Results: We cataloged TERT genetic alterations (i.e., promoter point mutations or structural variations), allele-specific promoter methylation patterns, and allele-specific expression levels in a cohort of 54 cancer cell lines. In heterozygous mutant cell lines, the mutant alleles were significantly less methylated than their silent, mutation-free alleles (p < 0.05). In wild-type cell lines, by contrast, both epialleles were equally methylated to high levels at the TERT distal promoter, but differentially methylated in the proximal regions. ChIP analysis showed that epialleles with the hypomethylated proximal and core promoter were enriched in the active histone mark H3K4me2/3, whereas epialleles that were methylated in those regions were enriched in the repressive histone mark H3K27me3. Decitabine therapy induced biallelic expression in the wild-type cancer cells, whereas the mutant cell lines were unaffected. Conclusions: Long-read bisulfite sequencing analysis revealed differences in the methylation profiles and responses to demethylating agents between TERT wild-type and genetically altered cancer cell lines. The causal relation between TERT promoter methylation and gene expression remains to be established.

24 October 2024 in Oncogene
Verified
Journal Article
Open access
PDF file
JHJoseph Hsieh
Joseph Hsieh
EDEtienne P. Danis
Etienne P. Danis
COCharles Owens
Charles Owens
JPJanet K. Parrish
Janet K. Parrish
NNNathan L. Nowling
Nathan L. Nowling
PJPaul Jedlicka
Paul Jedlicka
Rhabdomyosarcoma (RMS), a malignancy of impaired myogenic differentiation, is the most common soft tissue pediatric cancer. PAX3-FOXO1 oncofusions drive the majority of the clinically more aggressive fusion-positive rhabdomyosarcoma (FP-RMS). Recent studies have established an epigenetic basis for PAX3-FOXO1-driven oncogenic processes. However, details of PAX3-FOXO1 epigenetic mechanisms, including interactions with, and dependence on, other chromatin and transcription factors, are incompletely understood. We previously identified a novel disease-promoting epigenetic axis in RMS, involving the histone demethylase KDM3A and the ETS1 transcription factor, and demonstrated that this epigenetic axis interfaces with PAX3-FOXO1 both phenotypically and transcriptomically, including co-regulation of biological processes and genes important to FP-RMS progression. In this study, we demonstrate that KDM3A and ETS1 colocalize with PAX3-FOXO1 to enhancers of important disease-promoting genes in FP-RMS, including FGF8, IL4R, and MEST, as well as PODXL, which we define herein as a new FP-RMS-promoting gene. We show that ETS1, which is induced by both PAX3-FOXO1 and KDM3A, exists in complex with PAX3-FOXO1, and augments PAX3-FOXO1 chromatin occupancy. We further show that the PAX3-FOXO1/ETS1 complex can be disrupted by the clinically relevant small molecule inhibitor YK-4-279. YK-4-279 displaces PAX3-FOXO1 from chromatin and interferes with PAX3-FOXO1-dependent gene regulation, resulting in potent inhibition of growth and invasive properties in FP-RMS, along with downregulation of FGF8, IL4R, MEST and PODXL expression. We additionally show that, in some FP-RMS, KDM3A also increases PAX3-FOXO1 levels. Together, our studies illuminate mechanisms of action of the KDM3A/ETS1 regulatory module, and reveal novel targetable mechanisms of PAX3-FOXO1 chromatin complex regulation, in FP-RMS.

31 March 2023
Verified
Other
Open access
JSJoseph L Sottnik
Joseph L Sottnik
LVLauren Vanderlinden
Lauren Vanderlinden
MJMolishree Joshi
Molishree Joshi
ACAna Chauca-Diaz
Ana Chauca-Diaz
COCharles Owens
Charles Owens
DTDan Theodorescu
Dan Theodorescu

31 March 2023
Verified
Other
Open access
JSJoseph L Sottnik
Joseph L Sottnik
LVLauren Vanderlinden
Lauren Vanderlinden
MJMolishree Joshi
Molishree Joshi
ACAna Chauca-Diaz
Ana Chauca-Diaz
COCharles Owens
Charles Owens
DTDan Theodorescu
Dan Theodorescu

31 March 2023
Verified
Other
Open access
JSJoseph L Sottnik
Joseph L Sottnik
LVLauren Vanderlinden
Lauren Vanderlinden
MJMolishree Joshi
Molishree Joshi
ACAna Chauca-Diaz
Ana Chauca-Diaz
COCharles Owens
Charles Owens
DTDan Theodorescu
Dan Theodorescu